Abstract
There is increasing evidence that neoadjuvant chemotherapy in stage III pancreatic cancer resulted in higher rate of conversion surgery and improved survival. This study aims to investigate the practice pattern and how initial treatment strategy impact the outcome of stage III pancreatic ductal adenocarcinoma (PDAC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
